A nationwide recall covers 22 vials of Apothecary Pharma's tirzepatide injection because the firm could not assure their sterility, according to the Food and Drug Administration's enforcement record.
The recalled product is tirzepatide at 18 milligrams per milliliter in 4-milliliter multidose vials, with product code NDC 85091-001-18. The FDA record lists individual lot numbers and beyond-use dates, which identify when the prepared medication should no longer be used.
The same recall event includes one vial of a separate product, NAD+ at 200 milligrams per milliliter in a 6-milliliter vial. That product has NDC 85091-011-06, lot AP-202647 and an Oct. 13, 2026, beyond-use date. NAD+ is not tirzepatide.
The FDA lists the Cary, North Carolina, firm's action as voluntary, initiated Sept. 24 and classified Oct. 8. The record showed the recall as ongoing when checked Oct. 20.
The reason given is a lack of assurance of sterility. That does not establish that every recalled vial was contaminated. The entry does not provide an illness count or say how many affected vials reached New England.
The notice is specific to the named pharmacy, strengths, product codes and lots. Readers with an Apothecary Pharma vial can compare its label with the FDA's full list and ask their dispensing pharmacist or prescriber about that product. The record does not announce a recall of every tirzepatide product.
Sources: FDA enforcement record and full affected lot list, event 99952.